CL2020002796A1 - Derivados de gip y usos de estos - Google Patents

Derivados de gip y usos de estos

Info

Publication number
CL2020002796A1
CL2020002796A1 CL2020002796A CL2020002796A CL2020002796A1 CL 2020002796 A1 CL2020002796 A1 CL 2020002796A1 CL 2020002796 A CL2020002796 A CL 2020002796A CL 2020002796 A CL2020002796 A CL 2020002796A CL 2020002796 A1 CL2020002796 A1 CL 2020002796A1
Authority
CL
Chile
Prior art keywords
gip
relates
peptides
derivatives
nash
Prior art date
Application number
CL2020002796A
Other languages
English (en)
Inventor
Reedtz-Runge Steffen
Frederik Johan Hogendorf Wouter
Thøgersen Henning
Raymond Cox Nicholas
J Knerr Patrick
Dimarchi Richard
Finan Brian
F Lau Jesper
Liu Fa
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2020002796A1 publication Critical patent/CL2020002796A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a péptidos novedosos que son derivados de análogos del polipéptido insulinotrópico dependiente de la glucosa (GIP) que tienen una estabilidad física mejorada en solución y un perfil de acción prolongado. Más en particular, la invención se refiere a dichos péptidos que son agonistas del receptor de GIP y a su uso en el control del peso o para el tratamiento de enfermedades tales como la obesidad, la diabetes o la esteatohepatitis no alcohólica (NASH).
CL2020002796A 2018-05-04 2020-10-28 Derivados de gip y usos de estos CL2020002796A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666916P 2018-05-04 2018-05-04
EP18172827 2018-05-17

Publications (1)

Publication Number Publication Date
CL2020002796A1 true CL2020002796A1 (es) 2021-02-19

Family

ID=66440040

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002796A CL2020002796A1 (es) 2018-05-04 2020-10-28 Derivados de gip y usos de estos

Country Status (20)

Country Link
US (3) US10604555B2 (es)
EP (1) EP3788063B1 (es)
JP (2) JP6818940B2 (es)
KR (1) KR102379958B1 (es)
CN (1) CN112074531B (es)
AU (1) AU2019263674B2 (es)
BR (1) BR112020022027A2 (es)
CA (1) CA3097939A1 (es)
CL (1) CL2020002796A1 (es)
CO (1) CO2020014180A2 (es)
ES (1) ES2961384T3 (es)
IL (1) IL278171A (es)
MA (1) MA52483A (es)
MX (1) MX2020011427A (es)
PE (1) PE20210473A1 (es)
PH (1) PH12020551742A1 (es)
RU (1) RU2020136305A (es)
SG (1) SG11202010297UA (es)
TW (1) TWI707865B (es)
WO (1) WO2019211451A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
JP7526673B2 (ja) 2018-02-20 2024-08-01 インサイト・コーポレイション がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
RU2020136305A (ru) * 2018-05-04 2022-05-05 Ново Нордиск А/С Производные gip и пути их применения
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
KR102886962B1 (ko) * 2020-02-05 2025-11-17 일라이 릴리 앤드 캄파니 직렬 수지 반응기의 펩티드 합성기
CN115884982A (zh) 2020-03-06 2023-03-31 赛诺菲 作为选择性gip受体激动剂的肽
JP7736315B2 (ja) 2020-03-31 2025-09-09 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
KR20230106616A (ko) * 2020-11-09 2023-07-13 엠바크 바이오테크 에이피에스 타키키닌 수용체 매개 장애의 치료에 있어서의 화합물 및 이의 용도
JP7805659B2 (ja) 2021-06-23 2026-01-26 ペプトロン インコーポレイテッド セマグルチド又はその薬学的に許容可能な塩を含む徐放性製剤組成物
MX2024002845A (es) 2021-09-06 2024-04-30 Sanofi Sa Nuevos peptidos como agonistas potentes y selectivos del receptor de gip.
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023151594A1 (en) * 2022-02-11 2023-08-17 Hangzhou Sciwind Biosciences Co., Ltd. A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof
CN120500330A (zh) 2022-12-16 2025-08-15 佩特通公司 包含glp-1受体激动剂或其药学上可接受的盐的缓释型微球及其用途
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
EP4669662A1 (en) * 2023-02-24 2025-12-31 IP2IPO Innovations Limited COMPOUNDS
WO2025092778A1 (zh) * 2023-10-31 2025-05-08 深圳信立泰药业股份有限公司 Glp-1化合物及其制备方法与应用
CN120349392A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种gip激动剂化合物
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
EA020018B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Процессированные аналоги глюкозозависимого инсулинотропного полипептида
MX2011001031A (es) 2008-08-07 2011-04-26 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa.
KR20110043688A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
CA2733006A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
CA2784757A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
US9249181B2 (en) * 2010-09-13 2016-02-02 Amylin Pharmaceuticals, Llc C-terminal amidation of polypeptides
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
CA2822617A1 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9453062B2 (en) * 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2013003449A2 (en) 2011-06-27 2013-01-03 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
NZ702333A (en) * 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
US9340600B2 (en) * 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
CN104583233B (zh) * 2012-06-21 2018-10-23 印第安纳大学研究及科技有限公司 表现出gip受体活性的胰高血糖素的类似物
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
AR096440A1 (es) * 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
EP3189072B1 (en) 2014-09-05 2018-07-18 University of Copenhagen Gip peptide analogues
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
EP3226906B1 (en) * 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1 derivatives and uses thereof
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016138335A1 (en) 2015-02-27 2016-09-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US20190175744A1 (en) 2016-03-18 2019-06-13 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
WO2017210168A1 (en) 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Aqueously soluble and chemically stable depsi glucagon agonists
WO2018220123A1 (en) * 2017-05-31 2018-12-06 University Of Copenhagen Long-acting gip peptide analogues
RU2020136305A (ru) * 2018-05-04 2022-05-05 Ново Нордиск А/С Производные gip и пути их применения

Also Published As

Publication number Publication date
CA3097939A1 (en) 2019-11-07
EP3788063C0 (en) 2023-08-09
JP2020528925A (ja) 2020-10-01
US20220000982A1 (en) 2022-01-06
PH12020551742A1 (en) 2021-06-28
CN112074531B (zh) 2025-04-15
AU2019263674B2 (en) 2023-03-02
BR112020022027A2 (pt) 2021-02-02
US11633459B2 (en) 2023-04-25
KR102379958B1 (ko) 2022-04-01
JP6818940B2 (ja) 2021-01-27
RU2020136305A (ru) 2022-05-05
ES2961384T3 (es) 2024-03-11
US20190367578A1 (en) 2019-12-05
AU2019263674A1 (en) 2020-11-26
IL278171A (en) 2020-11-30
SG11202010297UA (en) 2020-11-27
PE20210473A1 (es) 2021-03-08
TWI707865B (zh) 2020-10-21
US10604555B2 (en) 2020-03-31
JP2020125311A (ja) 2020-08-20
KR20210005700A (ko) 2021-01-14
MA52483A (fr) 2021-03-10
US20240190938A1 (en) 2024-06-13
MX2020011427A (es) 2020-12-07
EP3788063B1 (en) 2023-08-09
WO2019211451A1 (en) 2019-11-07
CO2020014180A2 (es) 2021-01-29
EP3788063A1 (en) 2021-03-10
TW202003550A (zh) 2020-01-16
CN112074531A (zh) 2020-12-11

Similar Documents

Publication Publication Date Title
CO2020014180A2 (es) Derivados de gip y usos de estos
CY1122539T1 (el) Αναλογα γλυκαγονης
MX2023010869A (es) Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
PE20210162A1 (es) Analogos de incretina y sus usos
CO7400885A2 (es) Análogos de glucagón
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
CO2019006917A2 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
CL2019001683A1 (es) Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.
ECSP12012357A (es) Análogos del glucagón
CL2014003421A1 (es) Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
ECSP12011593A (es) Análogos de glucagón acilados
MX2016016868A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.
MX2017012864A (es) Analogo acilado del glucagon.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY33462A (es) Analogos de glucagon
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
MX377052B (es) Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
CL2020000812A1 (es) Semaglutida en la terapia médica.
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
MX2024000276A (es) Analogo de peptido de oxintomodulina acilado.
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
AR115077A1 (es) Derivados de gip y sus usos
ECSP15009978A (es) Análogos de glucagón